220 related articles for article (PubMed ID: 12732841)
1. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
[TBL] [Abstract][Full Text] [Related]
2. Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.
Lu JF; Blaschke TF; Flexner C; Rosenkranz SL; Sheiner LB;
Drug Metab Dispos; 2002 Dec; 30(12):1455-61. PubMed ID: 12433819
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
Hsu A; Granneman GR; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard JM
Clin Pharmacol Ther; 1998 Apr; 63(4):453-64. PubMed ID: 9585800
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
5. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
6. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects.
Zhang X; Fettner S; Zwanziger E; Rowell L; Salgo M
Antimicrob Agents Chemother; 2011 Feb; 55(2):680-7. PubMed ID: 21135186
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
Hoffmann F; Notheis G; Wintergerst U; Eberle J; Gürtler L; Belohradsky BH
Pediatr Infect Dis J; 2000 Jan; 19(1):47-51. PubMed ID: 10643850
[TBL] [Abstract][Full Text] [Related]
9. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
[TBL] [Abstract][Full Text] [Related]
11. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
12. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
Ford J; Boffito M; Wildfire A; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
Antimicrob Agents Chemother; 2004 Jul; 48(7):2388-93. PubMed ID: 15215085
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
14. Low-dose ritonavir moderately enhances nelfinavir exposure.
Kurowski M; Kaeser B; Sawyer A; Popescu M; Mrozikiewicz A
Clin Pharmacol Ther; 2002 Aug; 72(2):123-32. PubMed ID: 12189359
[TBL] [Abstract][Full Text] [Related]
15. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
[TBL] [Abstract][Full Text] [Related]
16. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.
Kaeser B; Zandt H; Bour F; Zwanziger E; Schmitt C; Zhang X
Antimicrob Agents Chemother; 2009 Feb; 53(2):609-14. PubMed ID: 19015329
[TBL] [Abstract][Full Text] [Related]
17. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.
Muirhead GJ; Wulff MB; Fielding A; Kleinermans D; Buss N
Br J Clin Pharmacol; 2000 Aug; 50(2):99-107. PubMed ID: 10930961
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
